AstraZeneca reported its first-quarter 2025 financial results, posting a core earnings per share (EPS) of $2.49, surpassing the estimated $2.26. The company's revenue reached $13.59 billion, slightly below the estimated $13.76 billion. AstraZeneca reiterated its full-year revenue and core EPS guidance. The profit increase was driven by strong sales of its diabetes and cancer medicines. However, the company also warned of mounting legal challenges in China. Despite beating earnings expectations, AstraZeneca's stock declined on the Stockholm stock exchange, with analysts citing two reasons for the market reaction. Additionally, several other companies, including Modivcare, Civeo, Vicarious Surgical, and Energy Vault, announced schedules for their first-quarter 2025 financial results or earnings conference calls.